Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI) (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Sponsor: Bausch Health Americas, Inc.
This observational or N/A phase trial investigates Fecal Incontinence and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Dec 2019 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jun 2019 — Dec 2019 [monthly]
Active Not Recruiting
▶ Show 5 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2017 — Dec 2017 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .